• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

超越算法:对 FDA 报告的涉及机器学习医疗器械的安全事件的分析。

More than algorithms: an analysis of safety events involving ML-enabled medical devices reported to the FDA.

机构信息

Centre for Health Informatics, Australian Institute of Health Innovation, Macquarie University, NSW 2109, Australia.

出版信息

J Am Med Inform Assoc. 2023 Jun 20;30(7):1227-1236. doi: 10.1093/jamia/ocad065.

DOI:10.1093/jamia/ocad065
PMID:37071804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10280342/
Abstract

OBJECTIVE

To examine the real-world safety problems involving machine learning (ML)-enabled medical devices.

MATERIALS AND METHODS

We analyzed 266 safety events involving approved ML medical devices reported to the US FDA's MAUDE program between 2015 and October 2021. Events were reviewed against an existing framework for safety problems with Health IT to identify whether a reported problem was due to the ML device (device problem) or its use, and key contributors to the problem. Consequences of events were also classified.

RESULTS

Events described hazards with potential to harm (66%), actual harm (16%), consequences for healthcare delivery (9%), near misses that would have led to harm if not for intervention (4%), no harm or consequences (3%), and complaints (2%). While most events involved device problems (93%), use problems (7%) were 4 times more likely to harm (relative risk 4.2; 95% CI 2.5-7). Problems with data input to ML devices were the top contributor to events (82%).

DISCUSSION

Much of what is known about ML safety comes from case studies and the theoretical limitations of ML. We contribute a systematic analysis of ML safety problems captured as part of the FDA's routine post-market surveillance. Most problems involved devices and concerned the acquisition of data for processing by algorithms. However, problems with the use of devices were more likely to harm.

CONCLUSIONS

Safety problems with ML devices involve more than algorithms, highlighting the need for a whole-of-system approach to safe implementation with a special focus on how users interact with devices.

摘要

目的

研究涉及机器学习(ML)启用的医疗器械的实际安全问题。

材料和方法

我们分析了 2015 年至 2021 年 10 月期间向美国 FDA 的 MAUDE 计划报告的 266 起涉及已批准的 ML 医疗器械的安全事件。根据现有的医疗信息技术安全问题框架,对事件进行了审查,以确定报告的问题是由于 ML 设备(设备问题)还是其使用引起的,以及问题的主要原因。还对事件的后果进行了分类。

结果

事件描述了具有潜在伤害风险的危害(66%)、实际伤害(16%)、对医疗保健服务的影响(9%)、若非干预则可能导致伤害的近因(4%)、无伤害或后果(3%)和投诉(2%)。虽然大多数事件涉及设备问题(93%),但使用问题(7%)导致伤害的可能性是其 4 倍(相对风险 4.2;95%CI 2.5-7)。将数据输入到 ML 设备的问题是导致事件的主要原因(82%)。

讨论

关于 ML 安全的大部分知识来自案例研究和 ML 的理论限制。我们对作为 FDA 常规上市后监测一部分捕获的 ML 安全问题进行了系统分析。大多数问题涉及设备,涉及算法处理数据的获取。然而,设备使用问题更有可能造成伤害。

结论

ML 设备的安全问题不仅涉及算法,还强调需要采用系统整体方法来实现安全,特别关注用户与设备的交互方式。

相似文献

1
More than algorithms: an analysis of safety events involving ML-enabled medical devices reported to the FDA.超越算法:对 FDA 报告的涉及机器学习医疗器械的安全事件的分析。
J Am Med Inform Assoc. 2023 Jun 20;30(7):1227-1236. doi: 10.1093/jamia/ocad065.
2
Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health.与软件相关的健康信息技术及其他医疗设备召回:对美国食品药品监督管理局数字健康监管的影响
Milbank Q. 2017 Sep;95(3):535-553. doi: 10.1111/1468-0009.12278.
3
How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?骨科器械在首次获得美国食品药品监督管理局(FDA)上市前批准后会发生怎样的变化?
Clin Orthop Relat Res. 2016 Apr;474(4):1053-68. doi: 10.1007/s11999-015-4634-x. Epub 2015 Nov 19.
4
Risk of Recall Among Medical Devices Undergoing US Food and Drug Administration 510(k) Clearance and Premarket Approval, 2008-2017.2008-2017 年美国食品和药物管理局 510(k) 审批和上市前批准的医疗器械召回风险。
JAMA Netw Open. 2021 May 3;4(5):e217274. doi: 10.1001/jamanetworkopen.2021.7274.
5
Adverse Events Involving Radiation Oncology Medical Devices: Comprehensive Analysis of US Food and Drug Administration Data, 1991 to 2015.涉及放射肿瘤学医疗设备的不良事件:1991年至2015年美国食品药品监督管理局数据的综合分析
Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):18-26. doi: 10.1016/j.ijrobp.2016.08.050.
6
Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015.1979 年至 2015 年初始食品和药物管理局上市前批准后眼科设备寿命期间的增量修订。
Ophthalmology. 2017 Aug;124(8):1237-1246. doi: 10.1016/j.ophtha.2017.03.040. Epub 2017 May 10.
7
Medical device recalls and the FDA approval process.医疗器械召回与美国食品药品监督管理局(FDA)的审批流程。
Arch Intern Med. 2011 Jun 13;171(11):1006-11. doi: 10.1001/archinternmed.2011.30. Epub 2011 Feb 14.
8
Conflicting information from the Food and Drug Administration: Missed opportunity to lead standards for safe and effective medical artificial intelligence solutions.来自食品和药物管理局的相互矛盾的信息:错失了引领安全有效的医疗人工智能解决方案标准的机会。
J Am Med Inform Assoc. 2021 Jun 12;28(6):1353-1355. doi: 10.1093/jamia/ocab035.
9
Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?医疗器械临床试验中的多样性:我们知道哪种方法对哪些患者有效吗?
Milbank Q. 2018 Sep;96(3):499-529. doi: 10.1111/1468-0009.12344.
10
FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012.1979 年至 2012 年,通过原始和补充上市前批准途径获得心脏植入式电子设备的 FDA 批准。
JAMA. 2014;311(4):385-91. doi: 10.1001/jama.2013.284986.

引用本文的文献

1
Robustness tests for biomedical foundation models should tailor to specifications.生物医学基础模型的稳健性测试应根据具体规格进行定制。
NPJ Digit Med. 2025 Aug 29;8(1):557. doi: 10.1038/s41746-025-01926-2.
2
Developing an AI Governance Framework for Safe and Responsible AI in Health Care Organizations: Protocol for a Multimethod Study.为医疗保健组织中安全且负责任的人工智能制定人工智能治理框架:一项多方法研究的方案
JMIR Res Protoc. 2025 Jul 28;14:e75702. doi: 10.2196/75702.
3
Advancements in materiovigilance: A comprehensive overview.药物警戒的进展:全面概述。
Perspect Clin Res. 2025 Jul-Sep;16(3):111-117. doi: 10.4103/picr.picr_66_24. Epub 2025 May 28.
4
Think FAST: a novel framework to evaluate fidelity, accuracy, safety, and tone in conversational AI health coach dialogues.思考FAST:一种评估对话式人工智能健康教练对话中的保真度、准确性、安全性和语气的新颖框架。
Front Digit Health. 2025 Jun 18;7:1460236. doi: 10.3389/fdgth.2025.1460236. eCollection 2025.
5
Proposing core competencies for physicians in using artificial intelligence tools in clinical practice.提出医生在临床实践中使用人工智能工具的核心能力要求。
Intern Med J. 2025 Aug;55(8):1403-1409. doi: 10.1111/imj.70112. Epub 2025 Jun 27.
6
A general framework for governing marketed AI/ML medical devices.用于管理上市人工智能/机器学习医疗设备的总体框架。
NPJ Digit Med. 2025 May 31;8(1):328. doi: 10.1038/s41746-025-01717-9.
7
User and Developer Views on Using AI Technologies to Facilitate the Early Detection of Skin Cancers in Primary Care Settings: Qualitative Semistructured Interview Study.用户与开发者对在基层医疗环境中使用人工智能技术促进皮肤癌早期检测的看法:定性半结构化访谈研究
JMIR Cancer. 2025 Jan 28;11:e60653. doi: 10.2196/60653.
8
The Future Hospital in Global Health Systems: The Future Hospital as an Entity.全球卫生系统中的未来医院:作为一个实体的未来医院。
Int J Health Plann Manage. 2025 May;40(3):730-740. doi: 10.1002/hpm.3893. Epub 2025 Jan 2.
9
The Challenges of Establishing Assurance Labs for Health Artificial Intelligence (AI).建立健康人工智能(AI)保证实验室的挑战。
J Med Syst. 2024 Dec 5;48(1):110. doi: 10.1007/s10916-024-02127-2.
10
Artificial intelligence related safety issues associated with FDA medical device reports.与美国食品药品监督管理局医疗器械报告相关的人工智能安全问题。
NPJ Digit Med. 2024 Dec 3;7(1):351. doi: 10.1038/s41746-024-01357-5.

本文引用的文献

1
The medical algorithmic audit.医学算法审计
Lancet Digit Health. 2022 May;4(5):e384-e397. doi: 10.1016/S2589-7500(22)00003-6. Epub 2022 Apr 5.
2
Quantification of Sepsis Model Alerts in 24 US Hospitals Before and During the COVID-19 Pandemic.24 家美国医院在 COVID-19 大流行前后对脓毒症模型警报的量化。
JAMA Netw Open. 2021 Nov 1;4(11):e2135286. doi: 10.1001/jamanetworkopen.2021.35286.
3
External Validation of a Widely Implemented Proprietary Sepsis Prediction Model in Hospitalized Patients.在住院患者中验证广泛实施的专有脓毒症预测模型的外部有效性。
JAMA Intern Med. 2021 Aug 1;181(8):1065-1070. doi: 10.1001/jamainternmed.2021.2626.
4
Artificial intelligence for clinical oncology.人工智能在临床肿瘤学中的应用。
Cancer Cell. 2021 Jul 12;39(7):916-927. doi: 10.1016/j.ccell.2021.04.002. Epub 2021 Apr 29.
5
Artificial intelligence in radiology: 100 commercially available products and their scientific evidence.放射学中的人工智能:100种商用产品及其科学证据。
Eur Radiol. 2021 Jun;31(6):3797-3804. doi: 10.1007/s00330-021-07892-z. Epub 2021 Apr 15.
6
How machine learning is embedded to support clinician decision making: an analysis of FDA-approved medical devices.机器学习如何嵌入以支持临床医生决策:对 FDA 批准的医疗设备的分析。
BMJ Health Care Inform. 2021 Apr;28(1). doi: 10.1136/bmjhci-2020-100301.
7
How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals.医学人工智能设备的评估方式:基于对美国食品药品监督管理局批准情况分析的局限性与建议
Nat Med. 2021 Apr;27(4):582-584. doi: 10.1038/s41591-021-01312-x.
8
Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015-20): a comparative analysis.美国和欧洲对人工智能和基于机器学习的医疗器械的审批(2015-20):比较分析。
Lancet Digit Health. 2021 Mar;3(3):e195-e203. doi: 10.1016/S2589-7500(20)30292-2. Epub 2021 Jan 18.
9
Application of Artificial Intelligence Technology in Oncology: Towards the Establishment of Precision Medicine.人工智能技术在肿瘤学中的应用:迈向精准医学的建立
Cancers (Basel). 2020 Nov 26;12(12):3532. doi: 10.3390/cancers12123532.
10
The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database.基于人工智能且获美国食品药品监督管理局批准的医疗设备及算法的现状:一个在线数据库。
NPJ Digit Med. 2020 Sep 11;3:118. doi: 10.1038/s41746-020-00324-0. eCollection 2020.